No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VRTX240712C495000
- 0.57
- -1.33-70.00%
15min DelayClose Jul 12 15:55 ET
2.66High0.57Low
2.66Open1.90Pre Close2 Volume21 Open Interest495.00Strike Price323.00Turnover130.27%IV1.40%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.57Extrinsic Value100Contract SizeAmericanOptions Type0.1678Delta0.0391Gamma857.44Leverage Ratio-21.7528Theta0.0001Rho143.91Eff Leverage0.0124Vega
Intraday
- 5D
- Daily
News
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Insider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
In the preceding three months, 13 analysts have released ratings for Vertex Pharmaceuticals (NASDAQ:VRTX), presenting a wide array of perspectives from bullish to bearish.The table below provides a
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -7.67% Morgan Stanley $402 → $455 Maintains Equal-Weight 06/27/2024 10.59% Redburn Atlantic → $
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
New York, USA, July 11, 2024 (GLOBE NEWSWIRE) -- Cystic Fibrosis Market is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech,
Comments
The 13F filing for the hedge fund led by the late Jim Simons (RIP) just dropped and we got you covered
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
+1
18
Keep an eye on these M&As: 👀
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
7
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
$Vertex Pharmaceuticals(VRTX.US$ reported on May 6 first quarter adjusted earnings and revenue that beat analysts' estimates.
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...
4
Read more
淡定的惠特莫爾 : Last time you asked me to buy sofi? A lot of falls
淡定的惠特莫爾 :
EZ_moneyOP 淡定的惠特莫爾: Sofi all you have to do is buy under 7 and hold. you don't lose unless you sell for a lost. hold until above 7 easy
淡定的惠特莫爾 EZ_moneyOP: Oh! Thank you
EZ_moneyOP 淡定的惠特莫爾:
View more comments...